SEC Form 4 · accession 0001209191-16-091547
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Oct 27, 2015
Accepted (ET)
Jan 14, 2016 · 9:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $48.74 | Jan 11, 2016 | G | 88,500 | D | — | Jul 24, 2022 | Common Stock | 88,500 | 29,500 | D |
| Stock Option (right to buy)F2,F1 | $48.74 | Jan 11, 2016 | G | 88,500 | A | — | Jul 24, 2022 | Common Stock | 88,500 | 88,500 | I |
| Stock Option (right to buy)F2,F3 | $45.11 | Jan 11, 2016 | G | 110,625 | D | — | Feb 4, 2023 | Common Stock | 110,625 | 66,375 | D |
| Stock Option (right to buy)F2,F3 | $45.11 | Jan 11, 2016 | G | 110,625 | A | — | Feb 4, 2023 | Common Stock | 110,625 | 110,625 | I |
Explanation of responses
- F1The option vests in 16 quarterly installments from 7/25/2012.
- F2Gift of options held by Dr. Leiden to a grantor retained annuity trust for the benefit of his immediate family members. Dr. Leiden maintains beneficial ownership over the shares subject to the options.
- F3The option vests in 16 quarterly installments from 2/5/2013.